Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled study.
Final on therapy Social Anxiety Scale-Adolescents and Children (SAS-AC) total score.
Secondary Outcome Measures :
Response, defined as a score of 1 (very much improved) or (very improved), on the Clinical Global Impressions-Improvement (CGI-I) scale; Final on therapy Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-AC) total score.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
8 Years to 17 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female outpatient
8-17 year old
diagnosis of Social Anxiety Disorder
concomitant psychiatric or medical disorders which interfere with safety or assessment